Drugs / Retatrutide
Retatrutide
Drug InvestigationalInvestigational triple hormone receptor agonist (GIP/GLP-1/glucagon)
- Registered trials
- 19
- Ongoing
- 10/ 53%
- Completed
- 8
- Indications
- 7
Approved indications
| Indication |
|---|
| Type 2 diabetes (investigational) |
| Obesity and overweight with at least one weight-related medical problem (investigational) |
| Knee osteoarthritis (investigational) |
| Moderate-to-severe obstructive sleep apnea (investigational) |
| Chronic low back pain (investigational) |
| Cardiovascular and renal outcomes (investigational) |
| Metabolic dysfunction-associated steatotic liver disease (investigational) |
Clinical trial landscape
19 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 3 | 14 | 9 | 5 | |
| Phase 1 | 3 | 1 | 2 | |
| Phase 2 | 1 | 0 | 1 | |
| Unknown | 1 | 0 | 0 | |
| All phases | 19 | 10 | 8 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Single molecule agonist of GIP, GLP-1, and glucagon receptors.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.